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A b s t r A c t
Glomerular diseases (GD) are characterized by lesions of the glomerular basement, 
which may be or may not be accompanied by inflammation and cellular hyperplasia. 
They are mainly classified as primary or secondary to a systemic disease. They are 
also classified as proliferative or non-proliferative diseases depending on the cellular 
infiltrate. Minimal change disease, focal segmental glomerulosclerosis and thin mem-
brane disease are non-proliferative, usually primary, glomerular diseases. Nephrotic 
syndrome is mainly the clinical syndrome that accompanies these GD. Proliferative 
GDs comprise IgA and IgM nephropathy, and crescentic GDs with or without immu-
nodeposits. Secondary proliferative GDs include systemic lupus erythematosous GD, 
vasculitides, and post-infection GDs. Non proliferative secondary GDs encompass 
diabetic nephropathy, amyloidosis, HIV nephropathy. Recent data on many aspects of 
GDs, i.e. pathogenesis and pathophysiology, diagnosis, therapy and other are briefly 
discussed in the present review.
I N t r O D U c t I O N
Glomerulopathies or glomerular diseases (GD) are renal diseases that affect both 
kidneys and are characterized by lesions of the glomeruli often accompanied by inflam-
mation of the mesangium and/or the glomeruli. Glomerular diseases have various clinical 
presentations (Table 1) that vary from the asymptomatic individual who is diagnosed 
at a routine medical assessment, to a patient with a fulminant illness with acute kidney 
injury. Patients can present with hematuria and/or proteinuria (nephritic syndrome), 
or as a nephrotic syndrome (heavy proteinuria), and/or acute or chronic renal injury.1
There are different types of glomerular syndromes that are categorized into several 
different pathological patterns. One classification divides the GD into primary and 
secondary. Primary GD is a disease confined to the kidney, while secondary GD is 
usually due to a systematic disease, such as diabetes, systemic lupus erythematosous 
(SLE), or vasculitis, or may be caused by drugs or certain infections that also affect 
the kidneys2 (Table 2). In this brief review we will describe the new developments in 
glomerular diseases related mainly to their pathogenesis, diagnosis and treatment.
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MMF = mycophenolate mofetil 
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M I N I M A L  c H A N G e  D I s e A s e  ( F i g .  1 )
Minimal change disease (MCD) is the main cause of ne-
phrotic syndrome in children younger than 10 years, in about 
50% to 70% of older children, and 10% to 15% of adults. It 
is thought to be a T-cell disorder mediated by a circulating 
factor that alters podocyte function resulting in proteinuria. 
In renal pathology and in light microscopy there is absence 
of histologic glomerular abnormalities, other than evidence of 
epithelial cell foot process fusion which is evident in electron 
microscopy. Corticosteroid-sensitive nephrotic syndrome is 
the term used to describe the disease occurring in children 
with nephrotic syndrome who respond to corticosteroids but 
who have not had a renal biopsy to provide the histologic 
tAbLe 1. Classification of Glomerulonephritis According 
to Clinical Presentation
common Glomerular Diseases Presenting as Nephrotic 
syndrome in Adults
Minimal change disease
Focal segmental glomerulosclerosis
Membranous nephropathy
Membranoproliferative glomerulonephritis I
Membranoproliferative glomerulonephritis II
Cryoglobulinemic membranoproliferative glomerulonephritis
Amyloid
Diabetic nephropathy
common Glomerular Diseases Presenting as Nephritic 
syndrome 
Poststreptococcal glomerulonephritis
Other postinfectious glomerulonephritis
IgA nephropathy
Lupus nephritis
common Glomerular Diseases Presenting as rapidly 
Progressive Glomerulonephritis
Goodpasture’s syndrome
Vasculitis 
Granulomatosis with polyangitis (Wegener’s) 
Microscopic polyangiitis
Pauci immune crescentic glomerulonephritis
Immune complex disease
Systemic lupus erythematosus
Poststreptococcal glomerulonephritis
IgA nephropathy/Henoch Schonlein purpura
FIGUre 1. Minimal Change Disease (MCD). Glomeruli with 
no lesions. H-Ex200.
tAbLe 2. Types of Glomerular Disease
Primary Glomerular Diseases
Minimal change disease
Membranous glomerulonephritis
Membranoproliferative glomerulonephritis
Focal segmental glomerulosclerosis
Mesangial proliferative glomerulonephritis  
(IgA Nephropathy, Henoch Schönlein purpura)
Anti GBM glomerulonephritis
ANCA associated glomerulonephritis, renal limited)
secondary Glomerular Diseases
Diabetes mellitus
SLE, systemic vasculitis
Lymphoma, solid tumors
Amyloidosis, multiple myeloma
Post-infectious glomerulonephritis  
(Malaria, endocarditis, HIV, HBV, HCV, other viruses)
Poststreptococcal glomerulonephritis
ANCA = anti-neutrophil cytoplasmic antibodies; GBM = glomerular 
basement mebrane; HBV = hepatitis B virus; HCV = hepatitis C virus; 
HIV = human immunodeficiency virus; SLE = systemic lupus erythe-
matosus
proof of MCD. Several times MCD appears to overlap with 
a variety of histologic variants that have a tendency to be less 
corticosteroid responsive. These conditions include focal 
segmental glomerulosclerosis (FSGS) and IgM nephropathy. 
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It is possible that both MCD and FSGS have similar initial 
histological appearances. Most cases are idiopathic, but they 
can also be secondary to neoplasias, such as Hodgkin’s disease, 
or secondary to administration of drugs (non-steroidal anti-
inflammatory drugs-NSAIDs, interferon alpha, etc.).1 
With regards to the new developments concerning MCD, 
there are some new insights into its pathogenesis. There is 
evidence that MCD is associated with a defect in the expres-
sion of cluster of differentiation 80 or CD80, a co-stimulatory 
molecule also known as B7.1, in the podocytes. This molecule 
(CD80) is expressed on all antigen-presenting cells and is also 
present on podocytes, as a number of experimental models of 
nephrotic syndrome suggest. This results in persistent defect 
of CD80 expression and persistent proteinuria. CD80 is also 
present in the urine during active nephrotic syndrome. CD80 
expression is known to be induced by Toll-like receptor (TLR) 
ligands in dendritic cells. For some authors, urinary excretion 
of CD80 is thought to be a useful marker to differentiate MCD 
from FSGS. In addition, studies have also shown that relapse 
of MCD is associated with a significant increase in measured 
urinary CD80, while patients in remission have no significant 
differences when compared to patients with FSGS.2-4 Other re-
cent studies on the molecular basis of MCD pathogenesis claim 
that overproduction of angiopoietin-like 4 protein (ANGPTL4) 
in podocytes in MCD, causes binding of this molecule to the 
glomerular basement membrane, leading to the development 
of diffuse effacement of foot processes, and loss of glomerular 
basement membrane charge and as consequence nephrotic-
range selective proteinuria.5 If everything is correct, these 
findings may lead to both new diagnostic tests and potential 
therapeutics for this important renal disease.
There are no new guidelines for the treatment of MCD 
in children or adults. Corticosteroids remain the mainstay of 
therapy in both cases and they are used both for initial therapy 
and for relapses. In frequent relapses and steroid-resistant 
MCD, or when corticosteroids are not well tolerated or not 
indicated, then cyclophosphamide or calcineurin inhibitors 
(CNIs) are the next therapeutic option in adults, while other 
alkylating agents such as chlorambucil can be given in chil-
dren. Mycophenolate mofetil (MMF) can also be used, while 
rituximab, a monoclonal antibody against B cell proliferation, 
is considered only in children with frequent relapses after 
optimal therapy with combinations of corticosteroids and 
corticosteroid sparing agents and/or in those who have serious 
adverse effects from previous therapies.1,6,7
M e M b r A N O U s  N e P H r O P A t H y  ( F i g .  2 )
Membranous nephropathy (MN) is the most common cause 
of nephrotic syndrome in adults. Clinically it is characterized 
by high-grade proteinuria with usually well preserved renal 
function. When renal biopsy is performed, there are typical 
immune deposits of IgG and complement components that 
develop predominantly or exclusively beneath podocytes in 
the subepithelial surface of the glomerular capillary wall. 
The disease occurs in association with a variety of conditions 
(Table 3). However, most of the cases of MN (about two 
thirds) are without obvious initiating events and are thought 
to be idiopathic. The rest may be caused by infections, drugs, 
autoimmune diseases or neoplasms.
Novel insights from experimental studies have been recently 
translated into substantial advances in understanding the patho-
genesis of human membranous nephropathy. These include 
identification of neutral endopeptidase (NEP), a membrane 
associated podocyte antigen that digests peptides, as the target 
FIGUre 2. Membranous Nephropathy (MN). A) Immunofluorescence: granular deposition of IgG along capillary walls. B) Mem-
branous nephropathy stage II, visible spikes of glomerular basement membrane (PASM ×600).
A b
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antigen in alloimmune MN resulting from feto-maternal im-
munization in NEP-deficient mothers, and the demonstration 
that a high proportion of patients with idiopathic MN have 
circulating antibodies to the M-type phospholipase A2 receptor 
(PLA2R), a transmembrane protein located on podocytes.8-10 
Given that the sensitivity and specificity of anti-PLA2R for 
idiopathic MN are >75% and 100%, respectively, there is 
hope that a widely available assay for anti-PLA2R will prove 
to be valuable for diagnosing idiopathic MN, distinguishing 
it from secondary MN, and evaluating response to therapy.
Newer data regarding the treatment of idiopathic membra-
nous nephropathy relate to the fact that immediate immuno-
suppressive therapy is reserved for patients with severe or life 
threatening symptoms associated with the nephrotic syndrome, 
while for those with a moderate disease, this therapy can be 
applied at a later stage, i.e. 6-8 months after its diagnosis fol-
lowing a conservative treatment.11 This first line of conservative 
treatment consists of antihypertensive agents which block the 
renin-angiotensin-aldosterone system (RAAS), while waiting 
for a possible spontaneous remission of the nephrotic syndrome 
which may happen in about 1/3 of cases.
When the criteria for immunosuppressive therapy are met 
(persistent nephrotic syndrome, hypoalbuminemia, etc.), the 
initial therapy that the new Kidney Disease Improving Global 
Outcomes (KDIGO) Foundation guidelines recommend, con-
sists of a 6-month course of alternating monthly cycles of oral 
and intravenous corticosteroids and oral cyclophosphamide. 
Alternative regimens include calcineurine inhibitors (CNIs, 
cyclosporine or tacrolimus). Monotherapy with MMF is not 
recommended as initial therapy for idiopathic membranous 
nephropathy.12 Rituximab, which selectively depletes B-cells, 
has been examined as an alternative option in the therapy of 
idiopathic MN and a clinical trial is running and soon there 
will be results of such treatment. Only case reports and case 
series have been published until now, with promising results 
in controlling proteinuria and achieving total or partial remis-
sion. Rituximab-induced depletion of PLA2R autoantibodies 
may play a critical role in predicting response to treatment. 
More large controlled studies are still needed to prove the ef-
fectiveness of this agent in the treatment of idiopathic MN.12-15 
F O c A L  s e G M e N t A L 
G L O M e r U L O s c L e r O s I s  ( F s G s )  ( F i g .  3 )
Focal segmental glomerulosclerosis (FSGS) is a common 
cause of nephrotic syndrome in children and adolescents, as 
well as an important cause of renal failure in adults. It defines a 
number of clinico-pathological syndromes that may be primary 
(idiopathic) or secondary to diverse etiologies. Genetic, toxic, 
infectious and inflammatory mediators have been identified.1 
The most common causes of secondary FSGS are virus induced 
(HIV1, parvovirus B19), drug induced (heroin, interferon, 
lithium, sirolimus) and postadaptive (reduced renal mass, 
hypertension, obesity, anabolic steroids). 
The genetic forms of FSGS can be part of a syndrome or 
can manifest as kidney limited disease. Mutations that are 
responsible for syndromic FSGS may include mutations in 
glomerular basement membrane proteins (Alport syndrome) 
and transcription factors that are important in podocyte dif-
ferentiation or metabolic disorders (Fabry’s disease). In renal 
limited disease the genetic mutations encode for proteins in 
the actin based cytoskeleton complex or the slit diaphragm 
complex and adhesive proteins (mutations in nephrin, podocin, 
actin, phospholipase C1, or in transient receptor potential 
cation 6 channel). Some of these familial FSGS syndromes 
are listed here. 
FA M I L I A L  F s G s
a. Autosomal recessive: Mutations in genes NPHS1 (cod-
ing for nephrin), NPHS2 (coding for podocin) and PLCE1 
(coding for PLC epsilon1), LAMB2 (coding for Laminin beta 
2 chain). b. Autosomal dominant: Mutations in genes ACTN1 
(coding for alpha actinin4), TRPC6 (coding for transient re-
tAbLe 3. Conditions and Agents Associated with Mem-
branous Nephropathy
Immune diseases SLE, diabetes, rheumatoid arthritis, 
Hashimoto disease, etc.
Infectious diseases Hepatitis B or C, syphilis
Drugs and toxins Gold, penicillamine, NSAIDs
Miscellaneous Tumors, sarcoidosis, sickle cell disease
NSAID = non-steroidal anti-inflammatory drugs; SLE = systemic 
lupus erythematosus
FIGUre 3. Focal segmental glomerulosclerosis (FSGS): Ad-
hesion of lobular part with Bowman capsule. Hypertrophy of 
podocytes (PASM ×400).
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ceptor potential cation 6 channel), INF2 (coding for INF2), 
WT1 (coding for WT1). All the mutations that are found in 
FSGS involve genes that are expressed in podocytes and this 
highlights the association between FSGS and podocyte injury. 
With regards to renal pathology, histologic variants of idi-
opathic focal segmental glomerulosclerosis may have prognostic 
value. A recent classification system (Columbia Classification 
system) has distinguished five variants depending on the ap-
pearance of histology16-18:
 - Cellular
 - Collapsing (affects younger and more often black patients)
 - Tip lesion
 - Perihilar
 - Not otherwise specified 
Irreversible podocyte stress leading to podocyte depletion 
through apoptosis or detachment is a critical mechanism in 
most forms of FSGS. In the collapsing variant, podocyte dys-
regulation leads to podocyte dedifferentiation and glomerular 
epithelial cell proliferation.
Primary focal segmental glomerulosclerosis has long been 
attributed to a circulating permeability factor. Indirect evidence 
is the ability to modulate proteinuria through immunoad-
sorption, the potential disease recurrence soon after renal 
transplantation and therapeutic reduction in proteinuria by 
plasmapheresis. In addition serum samples from patients with 
FSGS cause increased permeability to albumin in isolated 
glomeruli and induce foot process effacement and protein-
uria when injected to rats. Several plasma factors have been 
proposed. Elevated serum levels of soluble urokinase receptor 
have been identified in more than two thirds of patients with 
primary focal segmental glomerulosclerosis but not in those 
with minimal change disease or other glomerular diseases. 
Also increased levels of soluble urokinase receptor have been 
associated with higher probability of recurrent disease in the 
renal allograft.19 Circulating soluble urokinase receptor induces 
foot process effacement through the activation of podocyte 
β3 integrin, and its effect can be blocked in animal models 
by neutralizing antibodies targeting soluble urokinase recep-
tor.20,21 The cellular source and stimulants of the receptor in 
individuals with primary FSGS are unknown.
Therapy of idiopathic FSGS has not significantly changed 
over the last several years with corticosteroids remaining the 
initial recommended therapy. For steroid-resistant FSGS or if 
steroids cannot be used, cyclosporine or tacrolimus is an alter-
native therapy, while MMF and high dose dexamethasone is 
reserved for patients who are intolerant to cyclosporine. Plasma 
exchange, which is successful in treating some patients with 
recurrent FSGS in the renal allograft, has not proved useful 
in patients with disease in their native kidneys.
Another area of active research is the use of agents to 
prevent renal fibrosis in patients with FSGS. Pirfenidone, an 
oral TGF-β inhibitor, was used in 21 patients with FSGS and a 
declining glomerular filtration rate (GFR).22 The drug halted 
the decline of kidney function over time without altering either 
blood pressure or proteinuria. A study using an antibody to 
TGF-β is also ongoing in FSGS patients23.
I g A  N e P H r O P A t H y  ( F i g .  4 )
IgA nephropathy (IgAN) is a mesangial proliferative 
glomerulonephritis characterized by diffuse mesangial depo-
sition of IgA. IgAN is the most common primary glomeru-
lonephritis in the world. The prevalence rate varies across 
different geographical regions. In Europe this is about 30-40%.
The classic presentation (in 40-50% of the cases) is episodic 
FIGUre 4. IgA Nephropathy. A) Diffuse and severe deposition of IgA in the mesangium. (IgA X 600). B) Light microscopy. IgA 
Nephropathy: Diffuse hyperplasia of the mesangium (PAS×200).
A b
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frank hematuria which usually starts within a day or two of a 
non-specific upper respiratory tract infection as opposed to 
post-streptococcal glomerulonephritis which occurs some time 
(weeks) after initial infection. Less commonly, gastrointestinal 
or urinary infection can be the inciting cause. Secondary IgAN 
is uncommon. Cirrhosis, celiac disease, and HIV infection 
are all associated with a high frequency of glomerular IgA 
deposition. IgAN has been infrequently associated with a 
variety of other diseases, including dermatitis herpetiformis, 
seronegative arthritis (particularly ankylosing spondylitis), 
small-cell carcinoma, lymphoma (Hodgkin lymphoma and T-
cell lymphomas, including mycosis fungoides), disseminated 
tuberculosis, bronchiolitis obliterans, and inflammatory bowel 
disease (Crohn’s disease and ulcerative colitis). These are 
usually clinically evident at the time of biopsy.
With regards to novel findings in IgA nephropathy, it has 
been recognized for some time that one of the most consistent 
features of IgA nephropathy is an alteration in the complement 
of serum IgA1 O-glycoforms, with an overrepresentation of 
poorly galactosylated IgA1 O-glycoforms both in the serum 
and mesangial deposits of patients with IgA nephropathy.24 
New data suggest that poorly galactosylated IgA1 O-glyco-
forms might act either as autoantigens driving the formation 
of glycan-specific antibodies, or antigens for cross-reactive 
antimicrobial antibodies.25 Formation of these circulating and 
mesangial IgA-containing immune complexes appears pivotal 
to the pathogenesis of IgA nephropathy and there are strong 
in vitro data to support their role in activation of mesangial 
cells, induction of podocyte injury, and activation of proximal 
tubular epithelial cells.
The Oxford classification for IgA Nephropathy (2009) 
is a new pathological classification system that identifies six 
pathologic variables that could be used to interrogate prog-
nostic significance independent of the clinical data in IgA 
nephropathy.26 These variables are (1) mesangial cellularity 
score; (2) percentage of glomeruli showing segmental sclerosis; 
(3) endocapillary hypercellularity; or (4) cellular/fibrocellular 
crescents; (5) percentage of interstitial fibrosis/tubular atrophy; 
and finally (6) arteriosclerosis score.
Taking into consideration the results of clinical trials 
published over the past 10 years and taking into account the 
history of IgAN, the following therapeutic approach is now 
proposed.27-32
• Patients with micro-macrohematuria alone: annual check-
ups with urine evaluation.
• Patients with proteinuria >1g/day: RAAS blockers, starting 
with a minimal dose, and then increasing up to the highest 
tolerated dose. The purpose is to suppress proteinuria or to 
keep it <1g/day. In cases of persistent proteinuria >1 g/d, 
at least a six-month course of corticosteroids is needed. 
• Immunosuppressants (cyclophosphamide and azathioprine) 
should be reserved for patients with rapidly progressive 
renal failure or with vasculitic lesions (other than crescents) 
at histological examination. 
Further studies are required to determine the effective-
ness of tonsillectomy, MMF and Omega 3 fatty acids in the 
therapeutic treatment of patients with IgAN.27-32
L U P U s  N e P H r I t I s  ( F i g .  5 )
Lupus nephritis is a common and serious feature of sys-
temic lupus erythematosus (SLE). From 30% to 50% of SLE 
patients will have clinically evident renal disease at presenta-
tion. During follow-up, renal involvement will occur in 60% 
of young adults and a greater percentage of young children. 
Renal involvement is manifested by proteinuria, active urinary 
sediment with microhematuria, dysmorphic erythrocytes and 
erythrocyte casts, and hypertension. In many cases with major 
renal involvement, the nephritic syndrome develops in asso-
ciation with proliferative glomerulonephritis and a decline in 
glomerular filtration rate (GFR). Infrequently, renal disease 
in SLE patients presents with tubular disorders such as renal 
tubular acidosis (RTA) with hypokalemia (type 1 RTA) or 
hyperkalemia (type 4 RTA), thrombotic disorders associated 
with a secondary antiphospholipid syndrome and fibrillary 
glomerulonephritis.
Although lupus nephritis may affect all structures of the 
kidney, glomerular involvement has been the best studied com-
ponent, and it has been well correlated with the presentation, 
course, and treatment of the disease. For many years, the World 
Health Organization (WHO) classification of lupus nephritis 
was used. The 2003 modifications in the current International 
Society of Nephrology (ISN)/Renal Pathology Society (RPS) 
classification refine and clarify some of the deficiencies of the 
WHO classification. As in the WHO classification, the ISN 
FIGUre 5. Systemic Lupus Erythematosus (SLE) Nephritis. 
Diffuse hyperplastic nephritis. Development of crescents. (PAS 
×200).
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classification is based on light microscopy (LM), immuno-
fluorescence (IF), and electron microscopy (EM) findings.33
Abbreviated International Society of Nephrology/Renal 
Pathology Society (ISN/RPS) classification of lupus nephritis 
2003: 33
Class I Minimal mesangial lupus nephritis
Class II Mesangial proliferative lupus nephritis
Class III Focal lupus nephritis
Class IV Diffuse segmental (IV-S) or global (IV-G) lupus 
nephritis
Class V Membranous lupus nephritis
Class VI Advanced sclerosing lupus nephrititis
While therapies such as corticosteroids, cyclophosphamide 
and mycophenolate mofetil have improved outcomes in lupus 
nephritis, some patients have refractory disease or are unable 
to tolerate these agents.34-37 These limitations along with the 
better understanding of the immunopathogenesis of SLE 
have resulted in the development of new immunosuppres-
sive and immunomodulatory treatments for lupus nephritis. 
Novel strategies include B cell depletion by the monoclonal 
antibodies rituximab and epratuzumab, “immunomodulation” 
of pathologic antibodies to dsDNA by abetimus, blockade 
of T-cell costimulation of B cells by abatacept, belatacept, 
IDEC131 and BG9588 and blockade of B cell stimulation 
by belimumab.38,39 Goals for new therapies of lupus nephritis 
are: (1) prevention of relapse, (2) improved side effect profile, 
(3) treatment of refractory disease, and (4) prevention of the 
development of chronic interstitial fibrosis and progressive 
renal failure or end-stage renal disease. Preliminary results are 
promising but large controlled trials are needed before there 
can be safe widespread use of these agents.34-39. 
s y s t e M I c  v A s c U L I t I s  ( F i g .  6 )
The primary systemic vasculitides are a group of inflam-
matory diseases of unknown cause, which are usually fatal 
if untreated. Various attempts have been made to create a 
universally accepted classification scheme but still the clas-
sification of the vasculitides remains a matter of controversy. 
Some classification systems have focused on the size of the 
vessels, while several other classification schemes have been 
based on histologic findings.40 The most recent classification 
schema proposed by the American College of Rheumatology 
(ACR) uses both vessel size and type of inflammatory infiltrate. 
It classifies vasculitis as follows: polyarteritis nodosa (PAN), 
Churg-Strauss syndrome, granulomatosis with polyangiitis (for-
mer Wegener’s), hypersensitivity vasculitis, Henoch-Schönlein 
purpura, giant cell arteritis, Takayasu’s arteritis, granulomatous 
angiitis of the central nervous system, Berger’s disease, and 
Kawasaki disease.40,41
In 1994, the Chapel Hill Consensus Conference (CHCC) 
created an alternative schema for classification of the major 
types of vasculitis. According to the CHCC, the vasculitides 
are divided into large, medium, and small-vessel vasculitis. 
The largest subgroup comprises syndromes associated with 
circulating anti-neutrophil cytoplasm antibodies (ANCA)-
ANCA-associated systemic vasculitides (AASV). These include 
granulomatosis with polyangiitis (Wegener’s, GPA) microscopic 
polyangiitis (MPA), Churg-Strauss angiitis and renal limited 
vasculitis. The kidneys are targets for a variety of systemic 
vasculitides, especially those that affect small vessels, due to 
the large number and variety of renal vessels.40-43
The targets for small-vessel vasculitides are the glomeruli, 
and therefore the most common clinical renal manifesta-
tions are those of glomerulonephritis and include hematuria, 
proteinuria, and renal failure. Renal failure often has the 
characteristics of rapidly progressive glomerulonephritis in 
patients with granulomatosis with polyangiitis (Wegener’s) 
and microscopic polyangiitis but usually is less severe in those 
FIGUre 6. A) Immunofluorence in a vasculitic lesion: Rare im-
mune deposition of C3 in the mesangium (C3 x 600). B) Light 
microscopy. Fresh hypercellular crescent. (PASM x 400).
A
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with Churg-Strauss syndrome. The glomerulonephritis usually 
has necrosis and crescent formation and an absence or paucity 
of immunoglobulin deposition and is often designated pauci-
immune crescentic glomerulonephritis. When pauci-immune 
crescentic glomerulonephritis occurs in the apparent absence 
of systemic vasculitis, it is sometimes referred to as renal vascu-
litis, renal-limited vasculitis, or idiopathic rapidly progressive 
glomerulonephritis. The most common antigen specificities 
of ANCA in patients with vasculitis and glomerulonephritis 
are for proteinase 3 (PR3) and myeloperoxidase (MPO). In 
addition to ANCA, the cellular immune system contributes to 
the pathogenesis of the disease. ANCA-mediated degranula-
tion of neutrophils causes vasculitic damage; T cells drive 
granuloma formation, promote vasculitic damage by several 
different pathways, and enhance autoantibody production by B 
cells. Recently, complementary PR3 and lysosomal membrane 
protein-2 (LAMP-2) were suggested as novel autoantigens in 
vasculitides.43 New findings also indicate the importance of 
complement and dendritic cells.
The treatment of systemic and renal vasculitis is based on 
the use of steroids in combination with immunosuppressive 
agents, most commonly cyclophosphamide and recently MMF 
to induce remission. In the presence of severe renal disease, 
plasma exchange is often used as an adjunct to the pharmaco-
logical treatment. When remission is achieved, maintenance 
therapy with lower doses of steroids and less potent agents 
such as azathioprine is suggested.43-45
Two of the most important studies for the use of rituximab 
(an anti CD-20 monoclonal antibody that depletes B lym-
phocytes) in ANCA-associated vasculitis were conducted in 
2010.44,45 The RAVE trial compared rituximab to commonly 
use cytotoxic agents for induction of complete remission by 
six months in patients with severe ANCA associated vasculitis. 
The data provided by this large multicenter trial suggest that 
the regimen containing rituximab plus corticosteroids is not 
inferior to the standard regimen of cyclophosphamide and 
corticosteroids and it may even be superior for induction of 
remission in severe relapsing disease.44 The RITuXIVAS trial 
tried to assess the treatment response and rates of associated 
adverse events with the rituximab based regimen as compared 
with the cyclophosphamide based regimen. The researchers 
concluded that rituximab was not associated with a reduction 
in early severe adverse effects and both regimens were associ-
ated with the same frequency of mortality (18%).45
c O N c L U s I O N
New insights into the pathogenesis, diagnosis and treatment 
of glomerular diseases comprise the following developments. 
a) Minimal change disease (MCD): New data with regards 
to its pathogenesis relate to a defect in the expression of 
CD80, a co- stimulatory molecule (also known as B7.1) in the 
podocytes, which seems to represent a possible new marker 
of disease activity and a new target for therapy. Similarly, 
overproduction of angiopoietin-like 4 protein (ANGPTL4) 
in podocytes in MCD causes binding of this molecule to the 
glomerular basement membrane, diffuse effacement of foot 
processes, and loss of glomerular basement membrane charge 
and as a consequence nephrotic-range selective proteinuria, 
findings that could also lead to new targets of disease activity 
and treatment.
b) Membranous nephropathy. Regarding its pathogenesis, 
the demonstration that a high proportion of patients with 
idiopathic membranous nephropathy have circulating anti-
bodies to the M-type phospholipase A2 receptor (PLA2R), a 
transmembrane protein located on podocytes will prove to be 
valuable for diagnosing idiopathic membranous nephropathy, 
distinguishing it from secondary membranous nephropathy, 
and evaluating response to therapy. With regards to its treat-
ment, the new development concerns mainly the possible use 
of rituximab not only for persistent nephrotic syndrome but 
also as for first line treatment (studies are on-going). In any 
case, immunossupressive therapy is limited to non-responders 
to strict conservative treatment with a follow up of more than 
6-8 months.
c) FSGS. There are ongoing studies concerning the patho-
genesis of genetic forms. As for the primary FSGS and its 
pathogenesis, high levels of circulating soluble urokinase re-
ceptor have been identified in more than two thirds of patients 
with FSGS including those with recurrence in renal allograft, 
inducing foot process effacement through the activation of 
podocyte β3 integrin, and this effect can be blocked in animal 
models by neutralizing antibodies targeting soluble urokinase 
receptor. This seems to be a fascinating target for disease 
activity and therapy.
d) In IgA nephropathy new data regarding its pathogenesis 
suggest that poorly galactosylated IgA1 O-glycoforms might 
act either as autoantigens driving the formation of glycan-
specific antibodies, or antigens for cross-reactive antimicrobial 
antibodies leading to activation and injury of mesangial cells 
and podocytes. The Oxford Classification system helps to 
classify the disease, whilst, as far as therapy is concerned, it 
is now concluded that patients with proteinuria >1 g/d with 
or without renal impairment need cosrticosteroid treatment.
e) Lupus nephritis. There no concrete new developments 
regarding its pathogenesis but with regards to its treatment, 
new immunosuppressive and immunomodulatory treatments 
for lupus nephritis are now under investigation (B cell deple-
tion, blockade of B and T stimulation etc).
f) In systemic vasculitides, concerning their pathogen-
esis, recently, complementary PR3 and lysosomal membrane 
protein-2 (LAMP-2) were suggested as novel autoantigens in 
these diseases. New findings also indicate the importance of 
complement and dendritic cells in their pathogenesis. As for 
their treatment, the use of Rituximab has been proved not 
GLOMERuLAR DISEASES
25
inferior to the standard cytotoxic therapy with cyclophospha-
mide, whilst MMF takes its position as a potential treatment 
modality of ANCA associated vasculitides both as induction 
or maintenance therapy.
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